Merck Will Pay About $1 Billion In Cash -- For Peloton Therapeutics...

This company was in the process of going public, so there is a wealth of information in its S-1, as to what it does -- and what it hopes to do.

Do enjoy reading all about it. Clearly it impressed the oncology R&D mavens at Kenilworth. So now it will be part of their stable. Here's a bit, from The Street:

. . . .Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Peloton in exchange for an upfront payment of $1.05 billion in cash, the company said. Peloton shareholders also will be eligible to receive a further $1.15 billion contingent upon successful achievement of future regulatory and sales milestones for certain candidates.

Peloton's lead disease-fighting candidate, PT2977, is a so-called "novel oral HIF-2α inhibitor" - an oral treatment designed to fight late-stage development of renal cell carcinoma, or RCC, a form of skin cancer. . . .

Now you know. Onward, with my adult kids -- for one more day. . . smiling.

नमस्ते